Artificial intelligence (AI) uses personified knowledge and learns from the solutions it produces to address not only specific but also complex problems. Remarkable improvements in computational power coupled with advancements in AI technology could be utilised to revolutionise the drug development process. At present, the pharmaceutical industry is facing challenges in sustaining their drug development programmes because of increased R&D costs and reduced efficiency. In this review, we discuss the major causes of attrition rates in new drug approvals, the possible ways that AI can improve the efficiency of the drug development process and collaboration of pharmaceutical industry giants with AI-powered drug discovery firms.

人工智能（AI）使用个性化知识，并从其产生的解决方案中学习，以解决特定的问题以及复杂的问题。计算能力的显着提高与AI技术的进步相结合，可以用来彻底改变药物开发过程。当前，由于增加的研发成本和降低的效率，制药业在维持其药物开发计划方面面临挑战。在这篇综述中，我们讨论了新药批准中损耗率的主要原因，人工智能可以改善药物开发过程的效率以及制药行业巨头与以人工智能为动力的药物发现公司之间的协作的可能方式。